廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,041.17
    +30.50 (+1.01%)
     
  • 滬深300

    3,537.48
    +16.52 (+0.47%)
     
  • 美元

    7.8256
    0.0000 (0.00%)
     
  • 人民幣

    0.9222
    -0.0006 (-0.07%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0515
    +0.0000 (+0.02%)
     
  • 歐元

    8.4431
    +0.0025 (+0.03%)
     
  • 英鎊

    9.8680
    -0.0080 (-0.08%)
     
  • 紐約期油

    83.11
    -0.06 (-0.07%)
     
  • 金價

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin

    70,222.02
    -524.43 (-0.74%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success

  • Raymond James has downgraded Gossamer Bio Inc (NASDAQ: GOSS) to Market Perform from Outperform following the publication of sotatercept's Phase 3 data in NEJM.

  • The analyst has already thought that seralutinib would exhibit weaker efficacy than Merck & Co Inc's (NYSE: MRK) sotatercept in comparable populations.

  • Using Hodges-Lehman location shift (HLLS) statistic for 6MWD, Merck reported a difference of 40.8m in Phase 3 compared to LSMD of 24.9m in Phase 2, which makes the development path for seralutinib even more difficult.

  • Sotatercept reduced the risk of clinical worsening or death by 84%, supporting the adoption as the new standard of care on top of existing therapies.

  • Raymond James writes that Gossamer may need to run another Phase 2 as an add-on to sotatercept or a Phase 3 in FC III patients only.

  • Although Gossamer has additional development plans for seralutinib in pulmonary hypertension (PH) due to interstitial lung disease (PH-ILD), a confirmed plan is required.

  • The analyst also writes that while PAH program discontinuation would still be a negative catalyst, the market may view the event positively. Gossamer's CNS penetrant BTKi GB5121 currently offers an upside.

  • Price Action: GOSS shares traded flat at $1.74 on the last check Tuesday.

Latest Ratings for GOSS

Date

Firm

Action

From

To

Nov 2021

SVB Leerink

Maintains

Outperform

Aug 2021

SVB Leerink

Maintains

Outperform

Mar 2021

HC Wainwright & Co.

Reiterates

Buy

View More Analyst Ratings for GOSS

廣告

View the Latest Analyst Ratings

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.